423 476
[35] ClinicalTrials.gov.
https://clinicaltrials.gov/ .[36] Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint inhibition
in metastatic urothelial cancer. Eur Urol. In press.
http://dx.doi.org/ 10.1016/j.eururo.2017.03.047 .[37]
Kamat AM, Sylvester RJ, Bohle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:1935–44.[38]
Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory mole- cule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008; 14:4800–8.[39]
Hedegaard J, Lamy P, Nordentoft I, et al. Comprehensive transcrip- tional analysis of early-stage urothelial carcinoma. Cancer Cell 2016;30:27–42.[40]
Liu JS, Bell J, Sumati R. Cost per responder analysis from the Checkmate 025 phase III trial of nivolumab versus everolimus in previously treated patients with advanced renal cell carcinoma. Value Health 2016;19:A145.[41]
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus ever- olimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917–27.
[42]
Joseph RW, Chatta G, Vaishampayan U. Nivolumab treatment for advanced renal cell carcinoma: considerations for clinical practice. Urol Oncol 2017;35:142–8.[43]
Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 2016;7:12624.
[44]
Graff JN, Alumkal JJ, Drake CG, et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 2016;7:52810–7.
[45] Bensch F, Van der Veen E, Jorritsma A, et al. First-in-human PET
imaging with the PD-L1 antibody 89Zr-atezolizumab. AACR 2017,
April 2017.
[46]
Cella D, Grunwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:994–1003.
[47]
Vaughn DJ, De Wit R, Fradet T, et al. Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus inves- tigator-choice chemotherapy for previously treated advanced urothe- lial cancer. Genitourinary Cancers Symposium (ASCO-GU) 2017.
[48]
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative posi- tion paper. Ann Oncol 2016;27:559–74.
[49]
Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/ PD-L1. Clin Cancer Res 2017;23:1920–8.
[50]
Kourie HR, Awada G, Awada AH. Learning from the ‘‘tsunami’’ of immune checkpoint inhibitors in 2015. Crit Rev Oncol Hematol 2016;101:213–20.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 1 1 – 4 2 3
423